A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus (Q39684782)

14 September 2017

A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus (English)

1 reference

Venezuelan equine encephalitis

14 September 2017

1 reference

1 reference

1 reference

Venezuelan equine encephalitis virus

object named as

Venezuelan equine encephalitis virus

1 reference

Wei-Gang Hu

1

1 reference

14 September 2017

Amanda L Phelps

2

1 reference

14 September 2017

Scott Jager

3

1 reference

14 September 2017

Damon Chau

4

1 reference

14 September 2017

Charles C Hu

5

1 reference

14 September 2017

Lyn M O'Brien

6

1 reference

14 September 2017

Stuart D Perkins

7

1 reference

14 September 2017

Amanda J Gates

8

1 reference

14 September 2017

Robert J Phillpotts

9

1 reference

14 September 2017

Les P Nagata

10

1 reference

14 September 2017

language of work or name

English

0 references

publication date

25 June 2010

1 reference

14 September 2017

1 reference

14 September 2017

28

1 reference

14 September 2017

34

1 reference

14 September 2017

5558-5564

1 reference

Venezuelan equine encephalitis

14 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Biological weapons--a primer for microbiologists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Antibodies for the prevention and treatment of viral diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Biochemical and Antigenic Comparisons of the Envelope Glycoproteins of Venezuelan Equine Encephalomyelitis Virus Strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Antigenic analysis of the surface glycoproteins of a Venezuelan equine encephalomyelitis virus (TC-83) using monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Monoclonal antibody protects mice against infection and disease when given either before or up to 24 h after airborne challenge with virulent Venezuelan equine encephalitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Venezuelan equine encephalitis virus complex-specific monoclonal antibody provides broad protection, in murine models, against airborne challenge with viruses from serogroups I, II and III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Humanization and mammalian expression of a murine monoclonal antibody against Venezuelan equine encephalitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Humane endpoints are an objective measure of morbidity in Venezuelan encephalomyelitis virus infection of mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Manipulating sorting signals to generate co-expression of somatostatin and eGFP in the regulated secretory pathway from a monocistronic construct.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Studies on conditional gene expression in the brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Stable antibody expression at therapeutic levels using the 2A peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Expression of furin-linked Fab fragments against anthrax toxin in a single mammalian expression vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal ‘skip’

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Mechanism of neuroinvasion of Venezuelan equine encephalitis virus in the mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Pathogenesis of Venezuelan Equine Encephalitis Virus Infection in Mice and Hamsters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Inflammation is a component of neurodegeneration in response to Venezuelan equine encephalitis virus infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Review lecture. The blood‐brain barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Antibody gene-based prophylaxis and therapy for biodefence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Variants of Venezuelan equine encephalitis virus that resist neutralization define a domain of the E2 glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Synergistic interactions of antibodies in rate of virus neutralization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Viral escape from the neutralizing antibody response: the lymphocytic choriomeningitis virus model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

Viral persistence in vivo through selection of neutralizing antibody-escape variants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.06.038

10.1016/J.VACCINE.2010.06.038

7 January 2021

Identifiers

DOI

1 reference

14 September 2017

1 reference